Antiphospholipid antibodies (aPL), anti-b2-glycoagulant (LA) by standard coagulometric methods. Univariate analysis showed that patients positive for protein I (anti-b2-GPI) and anti-oxidized-lowdensity lipoprotein (LDL) antibodies are all implicanti-b2-GPI had a higher risk of recurrent thrombotic events (OR=3. 
Introduction
Antiphospholipid syndrome (APS) has been defined antibodies detected in conventional aCL and LA assays are phospholipid-binding plasma proteins or as the occurrence of thrombosis (arterial or venous), fetal loss and/or thrombocytopenia, in the presence complexes of these proteins with phospholipid. These proteins have been identified as ß2-glycoprotein I of antiphospholpid antibodies (aPL). Since the initial report,1,2 numerous studies have confirmed the strong (ß2-GPI) for aCL5-7 and prothrombin for LA.8,9 These autoantibodies seem to be not only markers of link between aPL, mainly anticardiolipin (aCL) and lupus anticoagulant (LA), and such symptoms, in disease, but also direct contributors to the development of thrombosis, fetal loss and thrombocytoppatients with both primary and secondary APS. 3, 4 Recent data indicate that the antigenic targets of enia.10-13 Antibodies binding to oxidized low-density lipoprotein (LDL) might also be considered aPL
Anticardiolipin antibodies
because LDL contains both phospholipid and a lipidaCL antibodies were determined by enzyme-linked binding protein-apolipoprotein B.14 Antibodies to immunosorbent assay (ELISA).22 oxidized LDL are associated with atherosclerosis15, 16 and arterial thrombosis. 17, 18 Lupus anticoagulant (LA)
Since these autoantibodies play a role in the pathogenesis, and they and their targets are extremely Because many patients were on Warfarin at the time heterogeneous, it is reasonable to assume that differof the study, data regarding LA were taken from the ent autoantibodies or combination of autoantibodies patient's files if available. A LA was present when will display distinct effects directly related to their prolonged dilute Russell's viper venom time was antigenic specificities, which might explain the corrected after platelet neutralization.23 observed clinical spectrum of APS.
In the present study, we sought to assess the Purification of b2-GPI association of these autoantibodies (aPL, anti-b2-GPI and anti-oxidized LDL) with APS symptoms, in an Human b2-GPI was purified by perchloric acid attempt to classify patients with APS into low-or treatment of normal plasma. Perchloric acid (2.5 ml) high-risk groups.
was added to 100 ml plasma, dropwise under constant stirring. It was left to stand for 30 min at 4°C with constant stirring and followed by centrifugation for 30 min (10 000 rpm, 4°C Irradiated microtitre plates (Dynatech) were coated or ultrasonography; pulmonary embolism by radiowith 100 ml/well of 10 mg/ml purified b2-GPI in nuclide lung scanning or angiography; thrombosis in 0.1M carbonate buffer (pH 9.5, coating buffer) overintracerebral vessels by computed tomographic scannight at 4°C. After washing three times with phosning, magnetic resonance imaging, or angiography; phate-buffered saline (PBS, 100 ml/well), plates were peripheral or mesenteric artery thrombosis by arterblocked with 1% BSA/PBS (100 ml/well) for 2 h at iography or at surgery). Retinal thrombosis was room temperature. Test serum samples diluted 1:100 diagnosed by ophthalmological examination. The in 1% BSA/PBS were then added to block plates diagnosis of myocardial infarction required an acute (50 ml/well). After 3 h incubation at room temperclinical presentation with typical electrocardioature, plates were washed with PBS and 50 ml/well graphic features and an elevated creatine kinase MB of conjugated alkaline phosphatase. Affinity-purified fraction. A diagnosis of cerebral transient ischaemic goat anti-human IgG (Sigma), diluted 1:500 in 1% attack required neurologic symptoms or signs lasting BSA/PBS, was added to each well and incubated for <24 h in a patient who met the criteria for the 1 h. Plates were then washed three times and 50 ml classification of cerebrovascular disease of the of 1 mg/ml p-nitrophenyl phosphate (Sigma) in diethNational Institute of Neurological Disorders and anolamine buffer (pH 9.8) was added. After 70 min., Stroke. 21 The diagnosis of amaurosis fugax was the absorbance was read at 405 nm. Rabbit antiestablished when sudden monocular blindness b2-GPI (Boehring), was used as a positive control of lasted <24 h.
antigen coating. For data analysis, we considered all symptoms Values higher than the mean+3SD of healthy suffered by the patients since the diagnosis of the donors were considered positive. APS until serum samples were obtained. Clinical data were taken from the patient's file
LDL isolation
Control sera for the anti-b2-GPI and anti-oxidized LDL antibodies were taken from 70 sex-matched LDL was isolated from pooled plasma of healthy fasting human donors by density gradient ultracentriyoung healthy donors. fugation at 65 000 rpm (Beckman L8-70, rotor VTI ated from odds ratios (OR) with a 95% confidence interval (95%CI). 65) for 35 min at 4°C and subsequently further purified in a second density gradient ultracentrifu-
For a more precise analysis, we distributed the values of anti-b2-GPI and anti-oxidized LDL antibodgation (49 000 rpm, 18 h, 4°C). The LDL was then dialysed against PBS (4°C for 30 h) (0.14 M ies in quartiles. The risk for the development of APSrelated disorders into the four categories defined for NaCl/0.01 M phosphate buffer).
anti-b2-GPI and anti-oxidized LDL antibodies was calculated by Likelihood Ratio (LR) in each quartile.24
Oxidation of LDL
Multivariate logistic regression analysis assessed Oxidized LDL was prepared by incubating the LDL the independent effects of the factors which showed for 3 h at 37°C with 0.5 M malondialdehyde (MDA) statistically significant association in the univariate at a constant ratio of 100 ml/mg of LDL. MDA was analysis. A logistic regression model was used (inclufreshly generated from MDA-bis-dimethylacetal by sion p<0.10 and exclusion p>0.15). For this anaacid hydrolysis: MDA-bis-dimethylacetal (88 ml) was lysis, aCL and LA were categorized as positive or incubated with 12 ml 4M HCl and 400 ml of water negative. Anti-b2-GPI and anti-oxidized LDL antiat 37°C for 10 min. The reaction was stopped by bodies were also divided into two categories: higher adjusting the pH to 7.4 with 1M NaOH, subsequently or lower than the mean value of patients. The adjusting the volume to 1 ml with distilled water.
autoantibodies were considered as independent variAfter conjugation, MDA-LDL was extensively diaables and the APS-related symptoms as dependent lysed against PBS to remove any unreacted MDA.
variables.
Anti-oxidized LDL antibodies
Microtitre plates for determination of anti-oxidized
Results
LDL antibodies were coated with either native or Table 1 shows the characteristics of patients. The with MDA-LDL, both at 10 mg/ml in PBS. The plates high number of female patients in this study is were incubated for 2 h at 37°C and overnight at probably due to referral bias to our SLE and APS 4°C. After washing four times with PBS, plates were pregnancy clinic. Of 102 women in the study, 79 blocked with 1% BSA/PBS for 2 h at room tembecame pregnant at some time during follow-up, perature. Serum samples were diluted 1:100 in and 49 had one or more fetal losses. No LA test was 1% BSA/PBS and incubated for 3 h at room performed in 23 patients who were receiving oral temperature. After washing, an alkaline phosphataseanticoagulant treatment. The mean (SD) for anticonjugated anti-human IgG (Sigma) was diluted b2-GPI antibodies was 0.23 (0.04) and that for anti-1:1000 in 1% BSA/PBS and added. It was left then oxidized LDL antibodies was 0.24 (0.18). for 3 h at room temperature. 1mg/ml p-nitroThere were no statistically significant differences phenyl-phosphate (Sigma) in 500 mM carbonate buffer containing 1mM MgCl 2 (pH 9.8) was used as LA, anti-ß2-GPI and anti-oxidized LDL) was estim- 
0024).
The association between anti-b2-GPI and aCL a higher risk of pregnancy loss (OR=4.62, p= 0.001).
antibodies and a history of pregnancy loss was also tested in a logistic regression model. This model We divided the values of anti-b2-GPI and antioxidized LDL antibodies into four quartiles, to deterincluded aCL and LA antibodies, smoking and treatment with Warfarin ( Table 5 ). The statistically signimine more precisely which values of these antibodies were associated with a higher risk of developing the ficant association between positive anti-b2-GPI antibodies levels and pregnancy loss disappeared. clinical associations found in the univariate analysis. A high level of anti-b2-GPI (highest quartile of Positive aCL antibodies test appeared as an independent risk factor for pregnancy loss (OR=5.63, p= distribution) showed the strongest association with the presence of recurrent thrombosis (OR=3. 17) 0.0043).
When the association between positive values of ( Table 3) . Anti-oxidized LDL antibodies levels above the p50 showed the highest risk for developing anti-b2-GPI antibodies and recurrent thrombotic events were tested, no possible confounding factors arterial thrombosis (OR=4.66). Levels above the p75 did not show statistical significance, probably appeared in the logistic regression model. Therefore, the OR value found in the univariate analysis was because of the small number of patients in this group (3 patients) ( Table 3) . not modified. The negative association between positive levels Statistically significant associations found in the univariate analysis were tested in multivariate logistic of anti-oxidized LDL antibodies and thrombocyto- ies may play a role in the development of arterial thrombosis. The mechanisms which can lead to arterial thrombotic events in APS remains unknown. Regression p Therefore, anti-oxidized LDL antibodies might be coefficient involved, due to shared common epitopes with aCL (SE) antibodies. Also, the presence of these antibodies may be an indirect meassure of serum high levels of We did not find a higher risk for venous thrombosis in patients with raised levels of anti-oxidized LDL case series, case-control studies, prospective followup studies and very few therapeutic clinical trials.
antibodies. It is known that when recurrent thrombosis was analysed in the same patient, an arterial Thus, we have still to identify the risk factors that might stratify patients at different likelihoods of thrombosis was followed by an arterial thrombosis in more than 90% of cases and a venous thrombosis developing clinical complications.
In contrast to previous studies,25,26 no correlation was followed by a venous thrombosis in more than 70%.32,33 Our data showed the same trend. These was found between the presence of aCL, anti-b2-GPI and LA with the first thrombotic event. This could results suggest that arterial and venous thrombosis might have different pathogenic mechanisms in APS possibly be due to either fluctuation in antibody levels or the retrospective nature of our study.
as in other thrombophilic disorders. Anti-oxidized LDL antibodies would be markers for arterial but not Our results show that positive values of antioxidized LDL antibodies were associated with arterial for venous thrombosis. No relationship between antioxidized LDL and fetal loss was found. thrombosis. These results agree with a recent study27 which showed a prevalence of anti-oxidized LDL In our study, a high level of anti b2-GPI antibodies (highest quartile of distribution) were associated with antibodies of 23.4% in APS patients and higher a 3.6-fold increase in the risk of recurrent thrombotic on the risk of pregnancy loss and thrombosis, and that it is difficult to quantify the associated risk with events. The presence of anti-b2-GPI34,35 and the IgG isotype of aCL antibodies36 have been widely associthe different aPL. Finally, a study from Rix et al.52 reported that the highest prevalence of fetal loss ated with primary thrombosis in APS. As far as we know, no risk factors for recurrent thrombotic events occurred in the subset of their cohort who had the highest levels of IgG aCL. Recent studies suggest that have been previously identified. Although this finding must be confirmed in prospective studies, it might anti-b2-GPI or anti-prothrombin antibodies are more closely associated with fetal loss and thrombosis have important therapeutic implications, since prophylactic treatment for recurrence of thrombosis in than aPL.34,53,54 In our study, although anti-b2-GPI antibodies appeared as a risk factor for pregnancy APS patients is still controversial.37 The most recent and largest retrospective studies32,33 suggest that these loss in univariate analysis, the logistic regression model containing aCL and LA, showed that antipatients should receive high-intensity Warfarin [International Normalized Ratio (INR) >3] on a b2-GPI antibody was only a confounding factor. The disparity between the literature and our own results long-term basis, to avoid recurrences. Only one prospective study has analysed the issue of prophymight be the consequence of different factors as the definiton for recurrent pregnancy loss, the variability lactic anticoagulant therapy in APS.38 In this study, the recurrent thrombotic events in 11 APS patients of the techniques to determine the different antibodies and the spontaneous fluctuations of these antiwith venous thrombosis and a control group of 34 patients with venous thrombosis but without APS bodies. In summary, in an attempt to identify subgroups were analysed. The follow-up time was 6 months. All were treated with Warfarin targeted to an INR of APS patients with different risks to develop APS related symptoms, we found that the risk for arterial between 2.0 and 3.0. Results showed a similar incidence of recurrences in both groups following thrombosis was increased in patients with levels of anti-oxidized LDL antibodies over the third quartile discontinuation of Warfarin. As this study had a small number of patients and a short follow-up, it is of distribution. Patients with the highest levels of anti-b2-GPI antibodies had a 3.1-fold increased risk uncertain whether these observations will be applicable to a larger series of APS patients over a longer of recurrent thrombotic events and patients with aCL antibodies had a higher risk of pregnancy loss. follow-up.
Forty-nine out of 79 (62%) pregnant women had Although these result must be confirmed by prospective studies, they might have important therapeutic miscarriages during the follow-up period. The results showed that the risk of fetal loss was associated consequences. only with the presence of aCL antibodies. The apparent association with anti-b2-GPI antibodies
